In this study, we employed MR to explore the causal relationships between cholesterol-lowering drug targets (HMGCR, PCSK9, and NPC1L1) and the risk of developing diabetic microvascular complications (including nephropathy, retinopathy, and neuropathy). The gene discussed is NPC1L1; the disease is retinal disorder.